Drug Profile
SER 109
Alternative Names: SER-109; VOWSTLatest Information Update: 25 Jun 2023
Price :
$50
*
At a glance
- Originator Seres Health
- Developer Seres Therapeutics
- Class Bacteria
- Mechanism of Action Bacteria replacements; Gastrointestinal microbiome modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Clostridium difficile infections
Most Recent Events
- 13 Jun 2023 Seres Health completes a phase II extension trial for Clostridium difficile infections (Recurrent) in USA (NCT02437500)
- 05 Jun 2023 Launched for Clostridium difficile infections (Prevention, Recurrent) in USA (PO)
- 07 May 2023 Efficacy and adverse event data from a phase III ECOSPOR IV trial in Clostridium difficile infection presented at the Digestive Disease Week 2023 (DDW-2023)